Read Larry Connors' blog – Short Term Trading Strategies
Rigshospitalet in Copenhagenhas ordered two new NovalisTxradiosurgery platforms and the associated suite of accessories and will upgrade an existing BrainLAB Novalis device to the more advanced new generation NovalisTx. All three machines will be equipped with Varian's RapidArc radiotherapy technology for image-guided, intensity-modulated radiotherapy (IMRT) treatments, meaning seven treatment machines at the hospital will have this new capability. They will also include the BrainLAB ExacTrac X-Ray 6D imaging system and the Varian On-Board Imager for precise patient positioning.
Dr. Svend Aage Engelholm, chief radiation oncologist of the Department of Radiation Oncology at CopenhagenUniversityHospital(Rigshospitalet), says, "The two new NovalisTxplatforms will mainly be used for state-of-the-art lung and prostate cancer treatments while most of the other extra-cranial stereotactic treatments will take place on the upgraded device," he said.
Dr. Engelholm added that Rigshospitalet has a long tradition of carrying out high-precision radiotherapy treatments and is one of the two leading hospitals in Denmarkfor stereotactic radiosurgery. The hospital was the first in Scandinaviato introduce IMRT treatments and was also the region's first hospital to offer image-guided radiotherapy (IGRT) as a routine preferred treatment for a number of cancer indications.
NovalisTxoffers radiosurgery for an extremely wide range of indications such as malignant and benign lesions, brain metastases, arteriovascular malformations, and functional lesions. It features very high dose delivery rates, which means that treatments can be delivered very rapidly. NovalisTxalso offers dynamic fine beam shaping and non-invasive, precise frameless patient positioning for rapid and comfortable treatments.
NovalisTxallows multiple beam energies of up to 18 million volts for treating deep-seated tumors. "The speed coupled with the precise beam shaping and advanced imaging capabilities make advanced radiosurgical treatments with NovalisTxmore affordable for hospitals and their patients," adds Dow Wilson, head of Varian's Oncology Systems business.
The Novalis Tx platform also includes an On-Board Imager device for pinpointing the tumor and positioning the patient with millimeter precision. The platform's ExacTrac room-based image-guidance system provides continual imaging during treatment to detect movement and support robotic adjustments in patient positioning in six dimensions. This enhances protection of surrounding healthy tissues while enabling clinicians to concentrate higher, more effective doses on tumors.
Jean Hooks, General Manager Oncology Solutions at BrainLAB, adds, "NovalisTxoffers extensive imaging capabilities with three complementary imaging systems. These are representative of the power our partnership with Varian brings to the field of radiosurgery. NovalisTxanswers strong demand from the clinical community for a fast, versatile, precise instrument that offers new hope to many cancer patients."
This latest investment at Rigshospitalet is part of a Denmark-wide strategy to ensure cancer patients receive their first radiotherapy treatment within four weeks of diagnosis. According to Dr. Engelholm, his hospital is on course to ensure most patients receive advanced radiotherapy treatment within two weeks of diagnosis.
About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 4,400 people who are located at manufacturing sites in North America and Europeand in its 60 sales and support offices around the world.
About BrainLAB
BrainLAB develops, manufactures and markets software-driven medical technology that enables procedures that are more precise, less invasive, and also less expensive than traditional treatments. Among the core products are image-guided systems that provide highly accurate real-time information used for navigation during surgical procedures. This utility has been further expanded to serve as a computer terminal for physicians to more effectively access and interpret diagnostic scans and other digital medical information for better informed decisions. BrainLAB solutions allow expansion from a single system to operating suites to digitally integrated hospitals covering all subspecialties from neurosurgery, orthopedics, ENT, CMF to spine & trauma and oncology. With more than 3000 systems installed in over 70 countries, BrainLAB is a market leader in image-guided technology. The privately held BrainLAB group, founded in 1989, is headquartered in Munich, Germanyand today employs more than 1000 people in 16 offices across Europe, Asia, Australia, North and South America.
CONTACT: Neil Madle, Varian Tel: +44 (0)7786 526 068 WWW: http://www.varian.com Eva Schuster, BrainLAB Tel: +49 89 991568 312 WWW: http://www.brainlab.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
